Therapeutic Potential of Emricasan, a Pan-Caspase Inhibitor, in Reducing Cell Death and Extracellular Matrix Accumulation in Fuchs Endothelial Corneal Dystrophy.

ECD analysis at 20 weeks showed a trend toward higher values in the emricasan group (n = 68) compared with the vehicle group (n = 35) (2067 ± 19 cells/mm 2 vs. 2019 ± 32 cells/mm 2 , respectively; p = 0.200).

also in 53,322 other papers

At 28 weeks, although the emricasan group showed a trend toward a smaller guttae area, the difference did not reach statistical significance (1.68 ± 0.09% vs. 1.89 ± 0.15%, respectively; p = 0.249) ( Figure 5 E). 3.6.

also in 111,027 other papers